SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

HCW Biologics Inc.
Date: May 1, 2025 · CIK: 0001828673 · Accession: 0000000000-25-004602

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
May 1, 2025
Author
Division of
Form
UPLOAD
Company
HCW Biologics Inc.

Letter

Re: HCW Biologics Inc. Draft Registration Statement on Form S-1 Submitted April 28, 2025 CIK No. 0001828673 Dear Hing Wong:

May 1, 2025

Hing Wong Chief Executive Officer HCW Biologics Inc. 2929 N Commerce Parkway Miramar, FL 33025

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: James Groth

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 1, 2025

Hing Wong
Chief Executive Officer
HCW Biologics Inc.
2929 N Commerce Parkway
Miramar, FL 33025

 Re: HCW Biologics Inc.
 Draft Registration Statement on Form S-1
 Submitted April 28, 2025
 CIK No. 0001828673
Dear Hing Wong:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: James Groth
</TEXT>
</DOCUMENT>